Resources Repository
-
EditorialPublication 2023Societal Perspective: Themed Issue on Productivity Costs, Consumption Costs, Informal Care Costs
Economic evaluations in healthcare assess the costs and benefits of new interventions, particularly pharmaceuticals, to …
Economic evaluations in healthcare assess the costs and benefits of new interventions, particularly pharmaceuticals, to inform funding and reimbursement decisions. These evaluations compare a new intervention against a relevant comparator, with the relevance of costs and benefits depending on the chosen perspective. The healthcare perspective, which assumes a fixed budget and aims to maximize health outcomes, considers only health impacts and costs within the budget. This approach simplifies the evaluation but may lead to suboptimal…
Cost-Effectiveness Analysis | Costing Methods | Health/Medicine -
OrganizationPublication 2024Based on Science
Since President Lincoln signed a congressional charter forming the National Academy of Sciences in 1863, …
Since President Lincoln signed a congressional charter forming the National Academy of Sciences in 1863, the National Academies have served the nation by drawing on the knowledge of the country’s top experts to deliver nonpartisan, objective advice on scientific matters. Based On Science uses the community of experts to provide the most up-to-date, evidence-based information about science and health questions that affect the decisions we make each day. This description was extracted from the Based…
Evidence Synthesis | Climate/Environment | Culture/Society | Energy/Engineering | Education/Labor | Health/Medicine | Science/Technology | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Probability/Bayes | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America